Publication | Closed Access

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

First-line TherapyHuman RetrovirusImmunologyClinical TrialsAntiviral Drug DevelopmentVirologyAntiviral TherapyPharmacotherapyHiv-1 InfectionAntiviral DrugHivMedicine